Clinical trials: Memory Dysfunction
Memory Loss
The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
To investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior.
- Trial name
- NCT00293176
- Testing
- Donepezil Hydrochloride
- Where
- 54 sites in United States
- Volunteers
- 821 people
- Sponsor
- Eisai Inc.
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236574
- Testing
- Galantamine hydrobromide
- Volunteers
- 974 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Cognitive Dysfunction, Memory Disorders
A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease
The purpose of this study is to test the use of a screening tool to detect changes in the eye that are associated with Alzheimer's disease in adult participants with memory issues.
- Trial name
- NCT07254234
- Testing
- Retinal scan, Blood test
- Where
- 3 sites in United Arab Emirates
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Memory Disorders, Alzheimer Disease
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
The proposed study is designed to evaluate the performance of the COGNISION™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairment
- Trial name
- COGNISION™ (NCT00938665)
- Testing
- COGNISION™ System
- Where
- 7 sites in United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Neuronetrix, Inc.
Alzheimer Disease (AD)
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
- Trial name
- NCT03518073
- Testing
- Zagotenemab
- Where
- 60 sites in United States, Canada and 1 more
- Volunteers
- 360 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, So Stated
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).
- Trial name
- NCT00422981
- Testing
- AL-108
- Where
- 17 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Allon Therapeutics
Mild Cognitive Impairment
Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.
Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain.
- Trial name
- NCT00040443
- Testing
- CX516
- Where
- 8 sites in United States
- Volunteers
- 175 people
- Sponsor
- RespireRx
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
The proposed study is designed to evaluate the performance of the ALTOIDA™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Disorders, Cognitive Impairment
- Trial name
- AltoidaML (NCT02843529)
- Testing
- Altoida: neuropsychological, MRI, EEG and CSF biomarkers
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Altoida
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236431
- Testing
- Galantamine hydrobromide
- Volunteers
- 1,063 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Memory Impairment, Age-related Cognitive Decline
Development of an Innovative Health Ingredient From Marine By-products for the Healthy Aging
This interventional, randomised, placebo-controlled and double-blind study aims to evaluate the effect of a dietary supplementation with a blue fish hydrolysate derived from marine by-products, containing peptides and n-3…
- Trial name
- BRAINBOOSTER (NCT04910399)
- Testing
- Blue fish hydrolysate
- Where
- 2 sites in France
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Abyss Ingredients
Alzheimer's Dementia
Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease
The purpose of this study is to determine if low level magnetic fields can help to improve memory in patients diagnosed with Alzheimer's dementia.
- Trial name
- NCT01195389
- Testing
- Resonator
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- pico-tesla Magnetic Therapies, LLC
Alzheimer Disease, Mild Cognitive Impairment
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Trial name
- QUIP II (NCT06025877)
- Testing
- PrecivityAD2(TM) blood test
- Where
- 9 sites in United States
- Volunteers
- 400 people
- Sponsor
- C2N Diagnostics
Mild Cognitive Impairment
A Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Participants With Mild Cognitive Impairment
The purpose of this study is to evaluate the psychometric properties of a Self-administered Memory Screening Test with Automated Reporting (SAMSTAR) adapted from the Rey Auditory Verbal Learning Test (RAVLT) in normal control…
- Trial name
- NCT02419183
- Testing
- SAMSTAR, RAVLT
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- Janssen Research & Development, LLC
Agitation Associated With Alzheimer's Disease, Alzheimer's Type
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.
- Conditions
- Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02192554
- Where
- 84 sites in United States, Bulgaria and 10 more
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Ischemic Stroke Hospitalized, Impairment, Cognitive
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
The goal of this clinical trial is to learn if Extract of Ginkgo Biloba Leaves Tablets help improve thinking and memory in people aged 55 years and older who had an ischemic stroke (a type of stroke caused by a blocked blood…
- Trial name
- GiCIIS (NCT07220538)
- Testing
- Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.), Standard of care (SoC) Group
- Where
- 40 sites in China
- Volunteers
- 400 people
- Sponsor
- Dr. Willmar Schwabe GmbH & Co. KG
Aging
Improvement in Memory With Plasticity-Based Adaptive Cognitive Training (IMPACT)
The primary objective of this study is to evaluate the effects of a computer-based training program on the memory and cognitive abilities of mature individuals undergoing healthy aging.
- Trial name
- IMPACT (NCT00283010)
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training, Educational DVDs
- Where
- United States
- Volunteers
- 487 people, healthy volunteers welcome
- Sponsor
- Posit Science Corporation
Cognitive Impairment, Brain Fog
A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Performance
This study evaluates the effects of the Xula Herbs Mind Food supplement on cognitive performance in adults aged 25-70 who report difficulty concentrating, memory challenges, brain fog, and low productivity.
- Conditions
- Cognitive Impairment, Brain Fog, Memory Difficulties, Difficulty Concentrating
- Trial name
- NCT07742605
- Testing
- Xula Herbs Mind Food Supplement
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Xula Wellness LLC